Patient
SITE015-0002
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2025-08-28
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-08-13 (study day 164); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-23 (study day 143); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 118); relationship: NOT RELATED
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-06-25 (study day 115); relationship: NOT RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 86); relationship: RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 77); relationship: not assessed
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-04-27 (study day 56); relationship: not assessed; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.